Navigation Links
AstraZeneca and Banner Alzheimer's Institute Collaborate to Evaluate New Tool Targeting Alzheimer's Disease

New Alliance Seeks to Advance Understanding of Disease and Clear Path for

New Treatments

WILMINGTON, Del. and PHOENIX, Dec. 19 /PRNewswire-FirstCall/ -- The Banner Alzheimer's Institute and AstraZeneca (NYSE: AZN) today announced that they will collaborate to help advance understanding of Alzheimer's disease and increase knowledge of potential new avenues for treatment through the use of cutting-edge brain imaging methods.

The new alliance will focus on the evaluation and further development of a radioligand discovered by AstraZeneca. This radioligand is a molecule that binds to amyloid plaque -- protein deposits in the brain that are a hallmark of Alzheimer's disease -- and allows the plaque to be measured in real time using a positron emission tomography (PET) scan.

Scientists at the Banner Alzheimer's Institute and AstraZeneca hope to use this new technology to find clues to how the disease progresses and affects the brain, offering a baseline for future studies. The information could potentially be used to monitor the effectiveness of existing treatments, reveal new therapeutic targets and enhance understanding of novel ways to curtail disease progression.

"We look forward to working with AstraZeneca on the development of this promising research tool for the early detection, tracking and scientific study of Alzheimer's disease in the living human brain," said Dr. Eric Reiman, executive director of the Banner Alzheimer's Institute. "Our goals are to advance the scientific understanding of Alzheimer's disease and evaluate promising disease-slowing and prevention therapies in the most rapid and rigorous way."

Alzheimer's disease is the most common form of dementia and affects more than 5 million Americans (1). Little is known about what causes this fatal condition or how it progresses in patients.

"Collaborating with the world-class researchers at the Banner Alzheimer's Institute means that together we can generate invaluable insights about Alzheimer's disease and we hope that this will facilitate the invention and development of important new medicines to help patients afflicted with this dreadful disease," said Bob Holland, Vice President for Neuroscience at AstraZeneca.

"Researchers at the Banner Alzheimer's Institute have a long-standing reputation for excellent imaging research in the Alzheimer's field. This setting is ideal for further evaluation of our new radioligand with the potential for detailed mapping of amyloid deposits and early diagnosis of Alzheimer's disease," said Lars Farde, Chief Scientist for CNS and Pain Research at AstraZeneca.

This the second of several planned new alliances by AstraZeneca with leading academic and research institutions to address unmet medical needs through cutting-edge research across several disease areas, including Alzheimer's disease, chronic pain and psychiatric illnesses. The first collaboration in this series was an agreement with the University of Texas Southwestern Medical Center at Dallas, in September, which focused on depression and other psychiatric illnesses. These proposed new agreements complement existing AstraZeneca US-based alliances in neuroscience and other key therapeutic areas with world-class institutions.

About Alzheimer's disease

Alzheimer's disease is a brain disorder that destroys brain cells, causing problems with memory, thinking and behavior severe enough to affect work, lifelong hobbies or social life. Alzheimer's gets worse over time, and it is fatal. Today it is the seventh-leading cause of death in the United States (1).

About Banner Alzheimer's Institute

The Banner Alzheimer's Institute provides clinical care for patients with memory and thinking problems. It also offers education, referral and support services for family and caregivers, and conducts leading-edge research in clinical trials, brain imaging and genetics studies. The Institute is devoted to finding effective Alzheimer's disease-slowing and prevention treatments in the shortest time possible. Banner Alzheimer's Institute is owned and operated by Phoenix-based Banner Health, a nonprofit organization. For more information about Banner Alzheimer's Institute, please visit

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

In the United States, AstraZeneca is a $12.44 billion healthcare business with more than 12,000 employees. For nearly three decades, AstraZeneca has offered drug assistance programs side by side with its medicines, and over the past five years, has provided over $3 billion in savings to more than 1 million patients throughout the U.S. and Puerto Rico. AstraZeneca has been named one of the "100 Best Companies for Working Mothers" by Working Mother magazine and is the only large pharmaceutical company named to FORTUNE magazine's 2007 list of "100 Best Companies to Work For." In 2006, for the fifth consecutive year, Science magazine named AstraZeneca a "Top Employer" on its ranking of the world's most respected biopharmaceutical employers.

(1) The Alzheimer's Association, What is Alzheimer's,, accessed Nov. 26, 2007.

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
2. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
3. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
4. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
5. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
6. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
7. Solazyme Selected for National Institute of Standards and Technology Award
8. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
9. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
10. National Institutes of Health Awards $25.5M Contract to SRA
11. The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus
Post Your Comments:
(Date:11/24/2015)... N.J. (PRWEB) , ... November 24, 2015 , ... The ... the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, the ... through his or her work with turfgrass. , Clarke, of Iselin, N.J., ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... But unless it is bound to proteins, copper is also toxic to cells. ... at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 Paris ...   --> Paris from 17 th ... DERMALOG, the biometrics innovation leader, has invented the first combined ... on the same scanning surface. Until now two different scanners ... one scanner can capture both on the same surface. ...
(Date:11/12/2015)...  A golden retriever that stayed healthy despite having ... provided a new lead for treating this muscle-wasting disorder, ... of MIT and Harvard and the University of São ... Cell, pinpoints a protective gene that boosts ... The Boston Children,s lab of Lou Kunkel , ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):